Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $35.00.

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report). The company’s ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...